The world responded to the crisis at unprecedented speed, as leaders and experts focused on different ways to operate and succeed within the constraints of a new dynamic. One standout success we have all benefitted from is vaccine development, with notable vaccines from Pfizer/BioNTech, AstraZeneca, and Moderna.
As the world stopped, researchers and stakeholders from across the industry turned their attention to tackling the SARS-CoV-2 virus. But despite this focus, new challenges were ubiquitous. COVID-19 set new expectations for how quickly R&D can move; the Coalition for Epidemic Preparedness Innovations (CEPI) has since established a 100 Days Mission for responding to the next Disease X, but what needs to happen for this to become a reality?
